Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Aigen Investment Management LP's 8th Largest Position

Aigen Investment Management LP increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 780.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,367 shares of the biopharmaceutical company's stock after buying an additional 5,644 shares during the period. Regeneron Pharmaceuticals comprises about 0.8% of Aigen Investment Management LP's portfolio, making the stock its 8th biggest position. Aigen Investment Management LP's holdings in Regeneron Pharmaceuticals were worth $4,535,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. Proficio Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 30.5% during the fourth quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 72 shares during the period. Seizert Capital Partners LLC raised its position in Regeneron Pharmaceuticals by 18.6% in the fourth quarter. Seizert Capital Partners LLC now owns 54,304 shares of the biopharmaceutical company's stock worth $38,682,000 after acquiring an additional 8,529 shares in the last quarter. Oak Grove Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 48.0% in the fourth quarter. Oak Grove Capital LLC now owns 2,930 shares of the biopharmaceutical company's stock valued at $2,087,000 after acquiring an additional 950 shares during the period. Victory Capital Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 44.8% during the 4th quarter. Victory Capital Management Inc. now owns 139,891 shares of the biopharmaceutical company's stock worth $99,649,000 after purchasing an additional 43,282 shares in the last quarter. Finally, Keybank National Association OH grew its stake in shares of Regeneron Pharmaceuticals by 6.5% during the 4th quarter. Keybank National Association OH now owns 1,239 shares of the biopharmaceutical company's stock worth $883,000 after purchasing an additional 76 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN opened at $675.49 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company's 50 day simple moving average is $697.13 and its 200 day simple moving average is $859.13. The stock has a market capitalization of $73.85 billion, a PE ratio of 17.65, a P/E/G ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.86 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on REGN shares. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.